Lxbio Pharmaceuticals

Lxbio Pharmaceuticals is an emerging, private biotech company based in Lisbon, Portugal, operating in the high-growth sectors of antibody and bacteriophage therapies. It is developing a pre-clinical pipeline targeting therapeutic areas with significant unmet needs, including diabetic foot infections, ocular surface infections, atopic dermatitis, respiratory infections, and diabetic retinopathy. The company has made strategic infrastructure investments, inaugurating a dedicated biologics R&D and production unit, and is actively seeking investment to advance its innovative platforms and pipeline programs.

Integrated platform combining engineered monoclonal antibodies, bacteriophage therapies for resistant infections, and nanoparticle-based drug delivery systems.

In antibodies, Lxbio competes with global biopharma giants and numerous biotechs. In phage therapy, it is part of a emerging, niche field with specialized players like Adaptive Phage Therapeutics and PhageTech, competing to establish clinical and regulatory precedents. Its CRO services compete with established global and regional contract development and manufacturing organizations (CDMOs).